Navigation Links
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Date:1/23/2009

ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Penny Heaton, V.P., and Chief Medical Officer, will be presenting at the Phacilitate Vaccine Forum Washington 2009 conference on January 26, 2009 at the Grand Hyatt in Washington D.C. Dr. Heaton is participating in the Focus Session 'What benefits are single-use technologies and other novel vaccine manufacturing solutions providing in practice' and will be speaking to the Case Study: Virus-Like Particle (VLP) based vaccines for pandemic and seasonal influenza. Slides from the presentation will be posted on the Novavax website at www.novavax.com.

There are several reasons for utilizing virus-like particle technology as a vaccine platform. Recombinant technology permits tailoring of vaccines to contain only those proteins that are immunologically important for protection and structurally important for optimizing expression and yields. In addition, preclinical and clinical data have shown that VLPs activate multiple arms of the immune system, inducing robust humoral and cell-mediated immunity, which permits vaccine development for a wide range of disease targets. Further, VLPs may be more cost effective to produce because vaccines against different disease targets may be manufactured utilizing the same process and facility. Dr. Heaton's presentation will discuss these advantages, with a specific focus on the potential immunologic and manufacturing benefits of Novavax's pandemic and seasonal influenza VLP vaccines.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Penny Heaton https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=63842


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
2. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
3. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
4. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
7. Novavax CEO to Present at BIO Investor Forum 2008
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Closing of $18 Million Registered Direct Offering
11. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):